Women's longevity: what changes in perimenopause?

Why women's longevity matters more now

Much of the longevity market's growth comes from women who demand better information about energy, recovery, sleep, body composition and brain health through hormonal transitions. It is an important part of the wider feminization of the market. Dansk Selskab for Gynækologi og Obstetrik (DSOG) PMID 35797481

It also makes sense in a broader healthtech perspective, because precision medicine, metabolic health and clinical processes take up more space in the conversation about women's health. But high interest is not the same as high quality evidence. Dansk Selskab for Gynækologi og Obstetrik (DSOG) PMID 35797481

Perimenopause is more than hot flashes

Many find that the first major challenge is not classic hot flashes, but poorer sleep, more restlessness, lower recovery, mood swings and greater difficulty in weight regulation. At the same time, muscle mass and insulin sensitivity may become more difficult to maintain. PMID 35797481 PMID 31839217

It is therefore insufficient to talk only about hormones. The functional assessment should also include strength, conditioning, body composition, blood tests, sleep and symptom patterns over time. PMID 35797481 PMID 31839217

Muscle mass, protein and metabolic health

After 40 and especially through menopause, muscle mass becomes even more important. Muscle is not just for appearance, but a central reserve for glucose handling, function, balance and long-term robustness. PMID 31839217 PMID 28815612

This means that strength training, sufficient protein and regular cardio should often be prioritized over yet another supplement. Zone 2 and progressive strength training are a powerful combination. PMID 31839217 PMID 28815612

Technology can help, but not replace the clinic

Wearables like Oura Ring 4 and other sensors can make sleep, temperature trends and recovery more visible. Digital biomarkers and future multiomics are likely to further improve personalization. PMID 28815612 PMID 31591555

But caution applies especially here. If symptoms are severe, if bleeding is unusual, or if there are concerns about bones, heart or metabolism, professional evaluation is more important than app data. PMID 28815612 PMID 31591555

Clinical guidelines and evidence-based menopausal hormone therapy (MHT)

The transition from perimenopause to postmenopause is characterized by ovarian follicular depletion, precipitating an abrupt drop in 17-beta-estradiol and progesterone production. This hormonal deficit causes vasomotor symptoms and sleep fragmentation while accelerating biological aging within vascular endothelium, neural networks, and bone architecture. Dansk Selskab for Gynækologi og Obstetrik (DSOG) PMID 35797481

Leading gynecological guidelines (including NAMS and European consensus bodies) emphasize the clinical 'window of opportunity': initiating menopausal hormone therapy (MHT) within 10 years of the final menstrual period (and before age 60) confers robust cardioprotective and osteoprotective benefits with minimal adverse risk. Dansk Selskab for Gynækologi og Obstetrik (DSOG) PMID 35797481

Modern protocols strictly favor transdermal bioidentical estradiol (gels or patches that bypass hepatic first-pass metabolism, carrying no elevated risk of deep vein thrombosis or stroke) paired with micronized bioidentical progesterone (Prometrium/Utrogestan), which preserves endometrial safety without the breast tissue proliferation linked to legacy synthetic progestins. Dansk Selskab for Gynækologi og Obstetrik (DSOG) PMID 35797481

Cardiometabolic shift: ApoB, visceral adipose deposition, and insulin resistance

Estrogen functions as a metabolic master regulator of lipid partitioning via estrogen receptor-alpha. With ovarian decline, lipid deposition shifts rapidly from subcutaneous gluteofemoral stores to visceral and intrahepatic depots, triggering an escalating burden of insulin resistance. PMID 31839217 PMID 31591555

Concurrently, atherogenic lipid fractions deteriorate: Apolipoprotein B (ApoB), LDL cholesterol, and triglycerides routinely increase by 10-20% within the first 24 months following menopause, while the atheroprotective functionality of HDL particles diminishes. PMID 31839217 PMID 31591555

Women thereby forfeit their premenopausal cardiovascular advantage relative to men. Proactive tracking of HOMA-IR, fasting glucose, blood pressure, and ApoB is imperative to intercept subclinical vascular pathology early. PMID 31839217 PMID 31591555

Bone mineral density (DEXA scanning) and osteoporosis prevention

The steepest rate of bone demineralization occurs during the early postmenopausal phase, where uncoupled osteoclastic activity outpaces osteoblasts, resulting in bone density losses of up to 2-3% annually. Dansk Selskab for Gynækologi og Obstetrik (DSOG) PMID 28815612

Obtaining a baseline dual-energy X-ray absorptiometry (DEXA) scan around age 50 establishes definitive T-scores (osteopenia between -1.0 and -2.5; osteoporosis below -2.5). In tandem with axial heavy resistance loading, targeted protein intake (1.6-2.0 g/kg), and co-supplementation of Vitamin D3 and K2, early surveillance guards against debilitating fragility fractures. Dansk Selskab for Gynækologi og Obstetrik (DSOG) PMID 28815612

The table below outlines the three distinct phases of reproductive senescence alongside targeted metabolic interventions. Dansk Selskab for Gynækologi og Obstetrik (DSOG) PMID 28815612